Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases.

摘要: In this study we have investigated changes in circulating angiogenic factors after a single zoledronic acid intravenous infusion. Thirty consecutive patients who had histologically confirmed breast (n = 20) and lung cancer 10) associated with confirmation of bone metastases were included the study. Serum was also available from 10 healthy volunteers. Four mg Zoledronic (Zometa, Novartis) administered as 15-min infusion 100-ml normal saline on an outpatient basis. Venous blood for assessment serum parameters drawn just before beginning drug again at 7 28 days levels VEGF bFGF assayed ELISA kits. not significantly different control groups (P > 0.05). However, found that higher than controls 0.009, P 0.022, respectively). We no significant correlation between levels. No statistically seen following both Unlike previous studies, did appear to exert activity there reduction